After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!

Quick Order

Text Size:AAA

Interferon beta / IFN-beta / IFNB Antibody, Mouse MAb

DatasheetReviewsRelated ProductsProtocols
Human IFNB1 Antibody Product Information
Immunogen:Recombinant Human IFNB protein (Catalog#10704-H02H)
Clone ID:4C2E1D2
Ig Type:Mouse IgG1
Concentration:
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human IFN-beta (rh IFNB; Catalog#10704-H02H; NP_002167.1; Met 1-Asn 187). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
Human IFNB1 Antibody Usage Guide
Specificity:Human Interferon beta / IFN-beta / IFNB
No cross-reactivity with Human IFNαG / IFN-Alpha G and Human cell lysate (293 cell line) in WB and ELISA
Application:ELISA

ELISA: 0.5-1 μg/mL

This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human IFNB. The detection limit for Human IFNB is 0.16 ng/well.

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Other IFNB1 Antibody Products
Reactivity: Human  
Application: ELISA  
    10704-MM22-100
    10704-MM22-50
    10704-MM22-200
    100 µg 
    50 µg 
    200 µg 
    Add to Cart
    Reactivity: Human  
    Application: ELISA  
      10704-T16-50
      10704-T16-100
      10704-T16-200
      50 µg 
      100 µg 
      200 µg 
      Add to Cart
      Reactivity: Human  
      Application: ELISA  
        10704-RP01-200
        10704-RP01-100
        10704-RP01-400
        200 µg 
        100 µg 
         
        Add to Cart
        Reactivity: Human  
        Application: ELISA  
          10704-RP02-50
          10704-RP02-100
          10704-RP02-200
          50 µg 
          100 µg 
          200 µg 
          Add to Cart
          Reactivity: Human  
          Application: ELISA  
            10704-R040-100
            10704-R040-50
            100 µg 
            50 µg 
            Add to Cart
            Interferon beta/IFN-beta/IFNB1 Background

            Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily, and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites and tumor cells. Interferon-beta (IFN beta) is an extra-cellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or cause autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis, and thus has therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of a chronic progressive CNS inflammation.

            Human Interferon beta/IFN-beta/IFNB1 References
          • Kohriyama T, et al. (2008) Interferon-beta treatment for multiple sclerosis and predictors of response. Nippon Rinsho. 66(6): 1119-26.
          • Stbgen JP. (2009) Recombinant interferon-beta therapy and neuromuscular disorders. J Neuroimmunol. 212(1-2): 132-41.
          • Abraham AK, et al. (2009) Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol. 77(12): 1757-62.
          • Product nameProduct name
            Size / Price
            Catalog: 10704-MM01-50
            List Price: 
            Price:      (You Save: )
            All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.
            Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"